Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking approach to diabetes management. These innovative therapies operate by mimicking the natural actions of GLP-1, a hormone secreted by the gut in response to meals. By stimulating GLP-1 receptors in the pancreas, these agents boost insulin secretion and inhibit glucagon sec

The burgeoning landscape of novel treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting considerable weight decrease – they exhibit intriguing variations in their